AHRQ examines vulnerable plaque
This article was originally published in The Gray Sheet
Executive Summary
More information is needed on whether medical therapy would change in patients who are not yet indicated for cardiovascular drugs such as statins but are found to have vulnerable plaque when screened using either a biomarker or an imaging procedure, the Agency for Healthcare Research and Quality says in an August 2010 technical brief. According to the report, "once the incremental predictive utility of detecting a vulnerable plaque is established, it will have to be demonstrated that certain treatments (novel or currently in use) in patients who would otherwise not have been candidates will indeed improve outcomes." Very few primary studies found through ARHQ's systematic review of research literature were conducted in patients without a known history of cardiovascular disease. The report notes that InfraReDx's LipiScan near-infrared imaging system has been cleared by FDA to detect lipid-core containing plaques. CMS recently denied the firm's request for a new-technology add-on payment for the device, saying there is insufficient evidence that patients scanned with the technology have better clinical outcomes (1"The Gray Sheet" Aug. 9, 2010)
You may also be interested in...
CMS Awards Monteris Add-On Payment For Tumor Ablation Catheter
Monteris Medical expects to deploy its AutoLITT tumor ablation catheter to the market "slowly and methodically" following a favorable Medicare reimbursement decision, according to Jim Duncan, the firm's CEO
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.